Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma

被引：0
|
作者：
Hans C. Lee
Noopur S. Raje
Ola Landgren
Vijay V. Upreti
Jin Wang
Ariel A. Avilion
Xuguang Hu
Erik Rasmussen
Gataree Ngarmchamnanrith
Hisaki Fujii
Andrew Spencer
机构：
[1] The University of Texas MD Anderson Cancer Center,Department of Lymphoma/Myeloma
[2] Harvard Medical School,Center for Multiple Myeloma, Massachusetts General Hospital
[3] Memorial Sloan Kettering Cancer Center,Myeloma Service, Department of Medicine
[4] Amgen Inc.,Clinical Pharmacology Modeling & Simulation
[5] Amgen Inc.,Bioanalytical Sciences
[6] Amgen Inc.,Clinical Biomarkers & Diagnostics
[7] Amgen Inc.,Global Biostatistical Science
[8] Amgen Inc.,Clinical Development
[9] Amgen Inc.,Translational Medicine
[10] Monash University,Malignant Haematology & Stem Cell Transplantation Service, The Alfred Hospital
来源：
Leukemia | 2021年 / 35卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：255 / 258
页数：3
相关论文
共 50 条
  • [31] Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
    Mailankody, Sham
    Liedtke, Michaela
    Sidana, Surbhi
    Matous, Jeffrey V.
    Chhabra, Saurabh
    Oluwole, Olalekan O.
    Malik, Shahbaz A.
    Kumar, Shaji
    Nath, Rajneesh
    Anwer, Faiz
    Cruz, Jose Carlos
    Jagannath, Sundar
    Htut, Myo
    Raje, Noopur S.
    Siegel, David S.
    Karski, Erin E.
    Lovelace, Wade
    Lourbakos, Afrodite
    Nandakumar, Srinand Ponnathapura
    Balakumaran, Arun
    Hari, Parameswaran
    BLOOD, 2021, 138
  • [32] BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
    Jagannath, Sundar
    Chanan-Khan, Asher A.
    Heffner, Leonard T.
    Avigan, David
    Lutz, Robert J.
    Uherek, Christoph
    Osterroth, Frank
    Ruehle, Markus
    Haeder, Thomas
    Niemann, Gabriele
    Wartenberg-Demand, Andrea
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    BLOOD, 2010, 116 (21) : 1262 - 1262
  • [33] An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
    Qingming Wang
    Runhong Wei
    Shufang Guo
    Chao Min
    Xiong Zhong
    Hui Huang
    Zhi Cheng
    Cancer Gene Therapy, 2024, 31 : 420 - 426
  • [34] Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
    Qu, Xiaoyan
    An, Gang
    Sui, Weiwei
    Wang, Tingyu
    Zhang, Xian
    Yang, Junfang
    Zhang, Yan
    Zhang, Lu
    Zhu, Dan
    Huang, Jiaqi
    Zhu, Shigui
    Yao, Xin
    Li, Jing
    Zheng, Chengxiao
    Zhu, Kevin
    Wei, Yutian
    Lv, Xiaoteng
    Lan, Liping
    Yao, Yihong
    Zhou, Daobin
    Lu, Peihua
    Qiu, Lugui
    Li, Jianyong
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (09)
  • [35] Preclinical Development of a Bcma Targeting Antibody-Drug Conjugate with Novel Payload for Multiple Myeloma Therapy
    Hau, Andrew
    Zhu, Tong
    Wang, Rengang
    Lau, Megan
    Li, Lingna
    Li, Xiaoqing
    Sun, Yingqing
    Kovacs, Ernest
    Khasanov, Alisher
    Deng, Dalun
    Yan, Zheng
    Knight, Robert D.
    Kaufmann, Gunnar F.
    Ji, Henry
    Li, Hui
    Zhang, Hong
    BLOOD, 2019, 134
  • [36] Pharmacodynamics of SEA-BCMA, a Nonfucosylated Antibody Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma
    Taft, David
    Henderson, Clark
    O'Day, Christine
    Yu, Changpu
    Li, Hong
    Ho, Phoenix
    Van Epps, Heather
    BLOOD, 2021, 138
  • [37] Phase II Study of Pembrolizumab in Multiple Myeloma Patients Relapsing after or Refractory to Anti-BCMA CAR-T Therapies
    Chung, Alfred
    Huang, Chiung-Yu
    Martin, Thomas
    Wolf, Jeffrey L.
    Wong, Sandy W.
    Shah, Nina
    BLOOD, 2022, 140 : 12651 - 12652
  • [38] Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease
    Deng, Haobin
    Liu, Meijing
    Yuan, Ting
    Zhang, Huan
    Cui, Rui
    Li, Jingyi
    Yuan, Jijun
    Wang, Xiaofang
    Wang, Yafei
    Deng, Qi
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [39] Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
    Cooper, Dennis
    Madduri, Deepu
    Lentzsch, Suzanne
    Jagannath, Sundar
    Li, Jingjin
    Boyapati, Anita
    Adriaens, Lieve
    Chokshi, Dhruti
    Zhu, Min
    Lowy, Israel
    Weinreich, David M.
    Yancopoulos, George D.
    Sharma, Manish
    Karasarides, Maria
    Sternberg, David
    BLOOD, 2019, 134
  • [40] Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
    Trudel, Suzanne
    Lendvai, Nikoletta
    Popat, Rakesh
    Voorhees, Peter M.
    Reeves, Brandi
    Libby, Edward N.
    Richardson, Paul G.
    Hoos, Axel
    Gupta, Ira
    Bragulat, Veronique
    He, Zangdong
    Opalinska, Joanna B.
    Cohen, Adam D.
    BLOOD CANCER JOURNAL, 2019, 9 (4)
12345